Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
National Institutes of Health Clinical Center (CC)
Viracta Therapeutics, Inc.
University of Liverpool
Juno Therapeutics, a Subsidiary of Celgene
Astex Pharmaceuticals, Inc.
Amgen
Nordic Nanovector
University of Colorado, Boulder
Celgene
Sunnybrook Health Sciences Centre
Takeda
Northwestern University
AbbVie
Baylor College of Medicine
Merck Sharp & Dohme LLC
Takeda
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Amgen Research (Munich) GmbH
Baylor College of Medicine
Baylor College of Medicine
Baylor College of Medicine
Baylor College of Medicine
Mayo Clinic
Eisai Inc.
New York Medical College
University of North Carolina, Chapel Hill
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
Wake Forest University Health Sciences
Amgen Research (Munich) GmbH
Mayo Clinic
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Radiation Therapy Oncology Group
Alliance for Clinical Trials in Oncology
Novartis
FDA Office of Orphan Products Development
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Children's Oncology Group
AVEO Pharmaceuticals, Inc.
Vifor Pharma